Sera Prognostics, Inc. (SERA) 股票分析

公司概述

Sera Prognostics, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company's primary commercialization effort involves the PreTRM test, a non-invasive blood test administered to pregnant women carrying a single fetus, targeting the specialized women's health market. In terms of scale, the entity lists with a market capitalization of $86.90M and employs a workforce of 71 individuals to support its R&D and commercialization activities. The reported annual revenue for the trailing twelve months stands at $81,000, a figure that, when combined with the market cap, indicates a highly capitalized company relative to its current operational output, suggesting significant potential for future expansion or a valuation based on future milestones rather than present cash flows. This disparity between market capitalization and revenue highlights that the company's market price is largely driven by investor expectations regarding its technology's future adoption in the U.S. healthcare system, rather than its current profitability or sales volume.

财务健康

The company reported a trailing twelve-month revenue of $81,000, yet it incurred a net income loss of $-31,928,000 and an EBITDA of $-35,680,000. The substantial gap between the negligible revenue and the multi-million dollar net loss reveals a cost structure heavily weighted toward research and development expenses and operational overheads that currently exceed all income generated from product sales. Free cash flow for the period was $-17,447,624, indicating that the company is burning cash at a rate that exceeds its minimal operating cash inflows, which limits immediate financial flexibility for capital expenditures without external financing. Margin analysis shows a gross margin of -102.5%, an operating margin of -89540.0%, and a profit margin of 0.0%, all of which point to severe operational inefficiencies or high fixed costs relative to sales, resulting in a total inability to generate profit from core operations. On the balance sheet, the company holds $39.20M in cash against $2.34M in debt, resulting in a debt-to-equity ratio of 3.10, which suggests a leveraged position where equity is low relative to obligations despite the significant cash hoard. The current ratio stands at 1.69, indicating that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer for liquidity management despite the negative cash flow. Return on equity is -51.8% and return on assets is -26.1%, metrics that reveal that management effectiveness is currently negative, as the capital invested by shareholders and creditors is generating losses rather than returns.

估值评估

The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is -3.31, implying that the market expects earnings to improve but the current multiple calculation remains distorted by negative projected earnings. The price-to-book ratio is 1.15, indicating that the market values the company at a slight premium over its book value, suggesting that investors are willing to pay more than the net asset value, potentially based on the perceived value of its intellectual property. The price-to-sales ratio is 1072.83, an exceptionally high multiple that suggests the market is pricing the stock based on future growth expectations rather than current sales performance. The enterprise value to EBITDA is -1.40, a negative metric that reflects the company's current inability to cover its capital structure with operating earnings, further complicating traditional valuation comparisons with profitable peers. The stock has a 52-week high of $4.09 and a 52-week low of $1.37, and without a specific current price listed in the provided facts, the valuation range is bounded strictly by these historical extremes which define the volatility envelope. The beta value of 1.06 indicates that the stock's price volatility is slightly higher than the broader market, meaning it tends to move with greater intensity than the general market index during periods of fluctuation.

Growth & Income

Revenue growth year-over-year is -58.3%, while earnings growth is N/A, indicating that the company is currently shrinking in terms of top-line sales rather than growing. The absence of positive earnings growth relative to revenue is inherent in the situation where revenue is contracting and losses are being incurred, implying a contraction phase in the business cycle or a failure to scale revenue to cover costs. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it reinvests its earnings—or rather, its remaining capital—into growth initiatives rather than returning value to shareholders through distributions. The overall growth and income profile is characterized by significant revenue contraction and negative returns, with no income generated for shareholders and a reliance on cash reserves to fund operations during this period of financial distress.